Solomon BJ, Shaw A, Ignatius Ou S-H, et al. Phase 2 Study of Lorlatinib in Patients with Advanced ALK/ROS1 Non-Small-Cell Lung Cancer. 18th World Conference on Lung Cancer (WCLC) 2017, abstract OA 05.06.
Durvalumab na chemoradiotherapie bij stadium III niet-kleincellig longcarcinoom
aug 2018 | Longoncologie